NKGen Biotech presents NK cell therapy data for Alzheimer's and Parkinson's at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit in Boston.
NKGen Biotech will present at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit, detailing their NK cell therapy in neurodegenerative disease. CEO Paul Y. Song will review preclinical data in Parkinson's disease, and share safety and efficacy data from NKGen's recent Phase 1 clinical trial of SNK01, an autologous natural killer cell therapy, in Alzheimer's disease. The presentation is scheduled for April 23-25 in Boston, MA.
April 18, 2024
3 Articles